ReviewJournal of clinical hypertension (Greenwich, Conn.)2007
Statins and C-reactive protein levels.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials.Cardiovascular research · 2024Pooled it
- Socioeconomic status in childhood and C reactive protein in adulthood: a systematic review and meta-analysis.Journal of epidemiology and community health · 2017Pooled it
- Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence.European journal of epidemiology · 2017Pooled it
- Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial.Archives of Iranian medicine · 2023Trial
- Effects of atorvastatin on human C-reactive protein metabolism.Atherosclerosis · 2013Trial
- Article
- Effect of Low-Carbohydrate Diets on C-Reactive Protein Level in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Food science & nutrition · 2025Review
- Predictors of Significant High-Sensitivity C-Reactive Protein Reduction After Use of Rosuvastatin/Amlodipine and Atorvastatin/Amlodipine-Subgroup Analysis in Randomized Controlled Trials.Journal of clinical medicine · 2025Article
- Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.European journal of clinical investigation · 2025Review
- Implications of Preoperative C-Reactive Protein Levels in Heart Transplant Patients-A Single-Center Retrospective Study.Journal of clinical medicine · 2024Article
- The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024Review
- Machine learning-based prediction model for the efficacy and safety of statins.Frontiers in pharmacology · 2024Article
- The Long Arm of childhood hypothesis and systematic low-grade inflammation: Evidence from parental education of older European adults.SSM - population health · 2023Article
- Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review.Cureus · 2022Review
- Development and Validation of a Risk Nomogram Model for Predicting Contrast-Induced Acute Kidney Injury in Patients with Non-ST-Elevation Acute Coronary Syndrome Undergoing Primary Percutaneous Coronary Intervention.Clinical interventions in aging · 2022Article
- Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The role of lovastatin in the attenuation of COVID-19.International immunopharmacology · 2021Article
- Visceral Adipose Tissue and Different Measures of Adiposity in Different Severities of Diffuse Idiopathic Skeletal Hyperostosis.Journal of personalized medicine · 2021Article
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2020Review
- Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study.Cardiovascular diabetology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with or at risk for cardiovascular disease (CVD), including hypertensive individuals, lowering levels of low-density lipoprotein cholesterol (LDL-C) reduces CVD risk. Statins are the most effective of available therapies for lowering LDL-C. Extensive clinical trial data have shown that the degree of LDL-C reduction obtained depends on the particular statin used and that intensive LDL-C lowering reduces the incidence of cardiovascular events compared with more moderate LDL-C lowering. More recent data suggest that effects independent of LDL-C lowering may also play a part in the reduction in cardiovascular events. C-reactive protein (CRP), a marker of inflammation, is a potential predictor of CVD risk, and statins reduce CRP levels by up to 60%. CRP reduction is independent of LDL-C lowering, and variation between statins in CRP reduction may play some role in CVD event reduction rates. At present, however, there are few outcome data relating to the cardiovascular benefits of reducing CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.